An open-label, single-arm study of prophylaxis for Datopotamab deruxtecan (Dato-DXd) -related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated non-small cell lung cancer.

Trial Identifier: D926UL00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo
Start Date: February 2026
Primary Completion Date: October 2027
Study Completion Date: October 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, AR Hot Springs National Park, AR, US, 71913
US, AR Little Rock, AR, US, 72205
US, AZ Tucson, AZ, US, 85719
US, CA Duarte, CA, US, 91010
US, CA Glendale, CA, US, 91204
US, CA Lakewood, CA, US, 90805
US, CA Torrance, CA, US, 90505
US, GA Athens, GA, US, 30607
US, IL Park Ridge, IL, US, 60068
US, IN Fort Wayne, IN, US, 46825
US, KY Lexington, KY, US, 40503
US, KY Louisville, KY, US, 40207
US, MI Detroit, MI, US, 48202
US, NC Greensboro, NC, US, 27403
US, NV Reno, NV, US, 89502
US, NY Westbury, NY, US, 11590
US, OH Cleveland, OH, US, 44106
US, TN Knoxville, TN, US, 37920
US, VA Fairfax, VA, US, 22031
US, WI Milwaukee, WI, US, 64111